Inmagene

Developing a portfolio of novel therapeutics for immune-mediated diseases. Lead candidate, IMG-007, an OX40 antagonist mAb with a silenced ADC function, is currently in 2 global Phase 2 clinical trials for atopic dermatitis and alopecia areata. Reverse merger announced December 2024 with Ikena Oncology to include IMG-007